Bausch + Lomb Corporation (BLCO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bausch + Lomb Corporation (BLCO) Healthcare & Pipeline Overview

Bausch + Lomb Corporation stands as a prominent player in the eye health sector, offering a comprehensive range of products across vision care, pharmaceuticals, and surgical instruments, thereby addressing diverse ocular health needs worldwide.

What Is the Investment Thesis for BLCO?

Bausch + Lomb Corporation is positioned for growth in the eye health market, which is projected to expand significantly due to increasing global demand for vision correction and treatment solutions. The company's diverse product portfolio, including high-margin surgical instruments and pharmaceuticals, supports a gross margin of 55.9%. The ongoing development of innovative products, particularly in the ophthalmic pharmaceuticals segment, is expected to drive revenue growth. Additionally, the company is actively exploring new therapeutic areas and geographic markets, which could enhance its market share and revenue streams. However, the company faces challenges such as a negative profit margin of -4.2%, which may impact its financial stability if not addressed promptly.

Based on FMP financials and quantitative analysis

BLCO Key Highlights

Market capitalization of $6.16B, indicating strong market presence.

• Gross margin of 55.9%, reflecting efficient cost management and product pricing.
• Employee base of 13,500, showcasing substantial operational capacity.
• Negative profit margin of -4.2%, highlighting potential financial challenges.
• Beta of 0.65, indicating lower volatility compared to the broader market.

Who Are BLCO's Competitors?

BLCO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BLCO's Key Strengths?

Established brand with a long history and strong market presence.

• Diverse product portfolio catering to various eye health needs.
• High gross margin indicating operational efficiency.
• Strong research and development capabilities fostering innovation.

What Are BLCO's Weaknesses?

Negative profit margin indicating potential financial instability.

• Dependence on specific product segments for revenue.
• Challenges in navigating regulatory environments across different markets.
• Limited presence in emerging digital health markets.

What Could Drive BLCO Stock Higher?

Launch of new ophthalmic pharmaceutical products expected in Q3 2026.

• Expansion of distribution channels in emerging markets to enhance market reach.
• Continuous investment in R&D to drive innovation in eye health solutions.
• Strategic partnerships with healthcare providers to enhance product accessibility.
• Marketing campaigns aimed at increasing brand awareness and consumer engagement.

What Are the Key Risks for BLCO?

Financial-distress signal — its Altman Z-Score of 0.96 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-3.4%) — the business is not currently generating profit on shareholder capital.
• Regulatory challenges that could delay product approvals.
• Competition from generic products impacting market share.
• Economic fluctuations affecting consumer spending on healthcare products.
• Supply chain disruptions that may impact product availability.

What Are the Growth Opportunities for BLCO?

• Growth opportunity 1: The global contact lens market is projected to grow from $10 billion in 2023 to $15 billion by 2028, driven by increasing prevalence of myopia and presbyopia. Bausch + Lomb's innovative lens technologies and expansion into emerging markets position it well to capture this growth.
• Growth opportunity 2: The ophthalmic pharmaceuticals segment is expected to experience a CAGR of 6% over the next five years, fueled by rising incidences of eye diseases such as glaucoma. Bausch + Lomb's focus on developing new therapies and expanding its product offerings can enhance its competitive edge.
• Growth opportunity 3: The surgical instruments market is anticipated to grow significantly, with a projected value of $25 billion by 2026. Bausch + Lomb's advanced surgical technologies and commitment to innovation can help it gain market share in this lucrative segment.
• Growth opportunity 4: With increasing aging populations globally, the demand for cataract surgeries is rising. Bausch + Lomb's comprehensive surgical solutions and strong distribution network position it to capitalize on this trend effectively.
• Growth opportunity 5: The expansion into digital health solutions, including telemedicine and remote monitoring for eye health, presents a new revenue stream. As healthcare increasingly embraces technology, Bausch + Lomb's initiatives in this area could lead to substantial growth.

What Threats Does BLCO Face?

• Intense competition from established and emerging players in the eye health sector.
• Potential regulatory changes impacting product approvals and market access.
• Economic downturns affecting consumer spending on healthcare products.
• Risks associated with patent expirations and generic competition.

What Are BLCO's Competitive Advantages?

• Strong brand recognition and reputation built over 170 years in the industry.
• Extensive patent portfolio protecting innovative products and technologies.
• Established relationships with healthcare providers and distribution channels.
• Commitment to research and development driving continuous product innovation.
• Diverse product offerings across multiple segments reducing reliance on any single market.

What Does BLCO Do?

Founded in 1853, Bausch + Lomb Corporation has established itself as a key player in the global eye health industry. Headquartered in Vaughan, Canada, the company operates through three primary segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment includes a wide array of contact lenses, ranging from daily disposables to frequently replaced options, along with lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating various eye conditions such as allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment focuses on both proprietary and generic products for post-operative care and treatments for conditions like glaucoma and retinal diseases, including therapeutic contact lenses. Meanwhile, the Surgical segment provides advanced tools and technologies for cataract surgery and other ocular procedures, including intraocular lenses, phacoemulsification equipment, and various surgical instruments. With a workforce of approximately 13,500 employees, Bausch + Lomb has a robust global presence, catering to diverse markets and maintaining a commitment to innovation and quality in eye health solutions.

What Products and Services Does BLCO Offer?

• Develops and manufactures a wide range of contact lenses for various wearing modalities.
• Offers over-the-counter eye care products, including eye drops and vitamins.
• Provides proprietary and generic ophthalmic pharmaceuticals for eye conditions.
• Supplies surgical instruments and technologies for cataract and retinal surgeries.
• Engages in research and development to innovate new eye health solutions.
• Operates globally, serving diverse markets with tailored products.

How Does BLCO Make Money?

• Generates revenue through the sale of contact lenses and eye care products.
• Offers surgical instruments and technologies to healthcare providers.
• Provides pharmaceutical products for eye health, including both branded and generic options.
• Invests in research and development to create innovative products that meet market needs.
• Utilizes a global distribution network to reach a wide customer base.

What Industry Does BLCO Operate In?

The medical instruments and supplies industry is experiencing robust growth, driven by increasing awareness of eye health and advancements in technology. The global ophthalmic market is expected to reach approximately $60 billion by 2027, with a CAGR of around 5%. Bausch + Lomb Corporation competes with key players such as Glaukos Corporation and Arrowhead Pharmaceuticals, leveraging its extensive product range and established brand reputation to capture market share. The ongoing trend towards minimally invasive surgical procedures is expected to further enhance demand for the company's surgical products.

Who Are BLCO's Key Customers?

• Eye care professionals, including optometrists and ophthalmologists.
• Retail pharmacies and optical shops selling consumer health products.
• Hospitals and surgical centers requiring advanced surgical instruments.
• Patients seeking vision correction and eye health solutions.
• Healthcare providers involved in the treatment of ocular diseases.

Company Profile

Bausch + Lomb Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Vaughan, CA. The company is led by CEO Brenton L. Saunders. BLCO has traded publicly since 2022.

Bausch + Lomb Corporation Financial Trajectory

Bausch + Lomb Corporation (BLCO) reported $1.39B in revenue for Jun 2026, reflecting 11.7% growth compared to the prior quarter. The company recorded a net loss of $14.0M, with diluted EPS of $-0.04. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, BLCO averaged $-0.12 in diluted EPS.

How Bausch + Lomb Corporation Is Valued

Bausch + Lomb Corporation carries a market capitalization of $6.16B, placing it in the mid-cap category. Analyst price targets span from $16.00 to $24.00, with a consensus of $20.20. At the current price of $17.25, that implies approximately 17% upside potential. Relative to its peer group, BLCO's quantitative score of 33/100 is below the peer average of 58/100.

Return on equity for Bausch + Lomb Corporation stands at -3.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.0%, the inverse of the P/E and a quick read on earnings relative to price.

Bausch + Lomb Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.96 places it in the distress zone, a signal of elevated financial risk.

Bausch + Lomb Corporation has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 33.2% below estimates on average.

Wall Street analysts project Bausch + Lomb Corporation revenue of about $5.50B for fiscal 2026, with EPS near $0.79. The estimate reflects 10 contributing analysts.

Over the past six months, Bausch + Lomb Corporation insiders filed 35 SEC Form 4 transactions — 12 sales and 23 purchases. On net that is roughly 415K shares acquired (about $873K) — insiders putting money in tends to read as conviction.

BLCO Financials

BLCO Latest News

BLCO Analyst Consensus

BLCO MoonshotScore

Latest Bausch + Lomb Corporation Analysis

Common Questions About BLCO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources